{"transactions":[{"id":700300,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":27622,"kind":"person","name":"Williamson Douglas J","position":1,"cik":"0001911501","reported_name":"Williamson Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-07-31T12:56:25.000Z","date":"2026-07-29","kind":"grant","planned":false,"acquired":true,"shares":40826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant."}],"balance_after":40826,"derivative":{"exercise_price":0.2433,"expiration_date":"2036-07-29","underlying":"Common Stock","underlying_shares":40826},"source":{"system":"sec-edgar","filing":"0001911501-26-000006","document":"form4-07312026_120720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1911501/000191150126000006/form4-07312026_120720.xml","form_type":"4"}},{"id":718487,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:34:09.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":36818,"price":0.1921,"value":7072.7378,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the \"ESPP\"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP."}],"balance_after":60868,"source":{"system":"sec-edgar","filing":"0001924908-26-000007","document":"form4-07022026_080703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000192490826000007/form4-07022026_080703.xml","form_type":"4"}},{"id":717696,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32788,"kind":"person","name":"Tressler Nick B.","position":1,"cik":"0001794362","reported_name":"Tressler Nick B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:17:25.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":11712,"price":0.1921,"value":2249.8752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":11712,"source":{"system":"sec-edgar","filing":"0001794362-26-000004","document":"form4-07022026_080720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000179436226000004/form4-07022026_080720.xml","form_type":"4"}},{"id":717698,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-02T20:16:44.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":36818,"price":0.1921,"value":7072.7378,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the \"ESPP\"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP."}],"balance_after":54846,"source":{"system":"sec-edgar","filing":"0001412071-26-000006","document":"form4-07022026_080729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141207126000006/form4-07022026_080729.xml","form_type":"4"}},{"id":771754,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":45967,"kind":"person","name":"Angelov Angel S","position":1,"cik":"0002132062","reported_name":"Angelov Angel S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-19T20:52:17.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted in connection with the Reporting Person's appointment as Chief Medical Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the stock options vest on May 18, 2027  (the \"Vesting Start Date\") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":0.5955,"expiration_date":"2036-05-18","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0002132062-26-000004","document":"form4-05192026_080513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000213206226000004/form4-05192026_080513.xml","form_type":"4"}},{"id":811403,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32788,"kind":"person","name":"Tressler Nick B.","position":1,"cik":"0001794362","reported_name":"Tressler Nick B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-04-10T00:43:16.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":75000,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001794362-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000179436226000002/edgardoc.xml","form_type":"4"}},{"id":811405,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-04-10T00:41:53.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":71268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":71268,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":71268},"source":{"system":"sec-edgar","filing":"0001412071-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141207126000004/edgardoc.xml","form_type":"4"}},{"id":811404,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-04-10T00:41:53.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":3732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":3732,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":3732},"source":{"system":"sec-edgar","filing":"0001412071-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141207126000004/edgardoc.xml","form_type":"4"}},{"id":811400,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-04-10T00:40:22.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":56248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":56248,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":56248},"source":{"system":"sec-edgar","filing":"0001998663-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000199866326000006/edgardoc.xml","form_type":"4"}},{"id":811399,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-04-10T00:40:22.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":18752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":18752,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":18752},"source":{"system":"sec-edgar","filing":"0001998663-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000199866326000006/edgardoc.xml","form_type":"4"}},{"id":811717,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53119,"kind":"person","name":"Cote Elissa S.","position":1,"cik":"0002069951","reported_name":"Cote Elissa S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Development Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-04-10T00:38:30.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":75000,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0002069951-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2069951/000206995126000004/edgardoc.xml","form_type":"4"}},{"id":811647,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-04-10T00:33:03.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":56247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":56247,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":56247},"source":{"system":"sec-edgar","filing":"0001924908-26-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000192490826000005/edgardoc.xml","form_type":"4"}},{"id":811646,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2026-04-10T00:33:03.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":18753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the \"Grant Date\"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date."}],"balance_after":18753,"derivative":{"exercise_price":0.5358,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":18753},"source":{"system":"sec-edgar","filing":"0001924908-26-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000192490826000005/edgardoc.xml","form_type":"4"}},{"id":950878,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-06T01:51:53.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":4386,"price":0.5626,"value":2467.5636,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":15249,"source":{"system":"sec-edgar","filing":"0001998663-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000199866326000002/edgardoc.xml","form_type":"4"}},{"id":980128,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32788,"kind":"person","name":"Tressler Nick B.","position":1,"cik":"0001794362","reported_name":"Tressler Nick B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock (Right to Buy)","published_at":"2025-12-04T11:07:03.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted in connection with the Reporting Person's appointment as Chief Financial Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the stock options vest on June 23, 2026 (the \"Vesting Start Date\") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":4.43,"expiration_date":"2035-12-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001794362-25-000005","document":"form4-12042025_111200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000179436225000005/form4-12042025_111200.xml","form_type":"4"}},{"id":1008012,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-04T21:34:49.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":35200,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant."}],"balance_after":35200,"derivative":{"exercise_price":3.9,"expiration_date":"2035-10-27","underlying":"Common Stock","underlying_shares":35200},"source":{"system":"sec-edgar","filing":"0001531178-25-000007","document":"form4-11042025_091145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000153117825000007/form4-11042025_091145.xml","form_type":"4"}},{"id":1042705,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-09-11T22:15:13.000Z","date":"2025-09-09","kind":"grant","planned":false,"acquired":true,"shares":17600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":17600,"derivative":{"exercise_price":3.61,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001411685-25-000076","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000076/edgardoc.xml","form_type":"4"}},{"id":1042703,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75505,"kind":"person","name":"Curley Joanne","position":1,"cik":"0001857670","reported_name":"Curley Joanne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-09-11T22:14:55.000Z","date":"2025-09-09","kind":"grant","planned":false,"acquired":true,"shares":17600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":17600,"derivative":{"exercise_price":3.61,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001411685-25-000075","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000075/edgardoc.xml","form_type":"4"}},{"id":1042704,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":50893,"kind":"person","name":"Cunningham Ann Michelle","position":1,"cik":"0001764572","reported_name":"Cunningham Ann Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-09-11T22:14:37.000Z","date":"2025-09-09","kind":"grant","planned":false,"acquired":true,"shares":17600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":17600,"derivative":{"exercise_price":3.61,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001411685-25-000074","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000074/edgardoc.xml","form_type":"4"}},{"id":1043184,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75534,"kind":"person","name":"SAXE JON S","position":1,"cik":"0001114914","reported_name":"SAXE JON S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-09-11T18:15:40.000Z","date":"2025-09-09","kind":"grant","planned":false,"acquired":true,"shares":17600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":17600,"derivative":{"exercise_price":3.61,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001411685-25-000078","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114914/000141168525000078/edgardoc.xml","form_type":"4"}},{"id":1043395,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75541,"kind":"person","name":"Rotunno Mary L.","position":1,"cik":"0001869200","reported_name":"Rotunno Mary L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-09-11T18:15:23.000Z","date":"2025-09-09","kind":"grant","planned":false,"acquired":true,"shares":17600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":17600,"derivative":{"exercise_price":3.61,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001411685-25-000077","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869200/000141168525000077/edgardoc.xml","form_type":"4"}},{"id":1097738,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-07-01T21:51:38.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":4882,"price":1.7,"value":8299.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":10863,"source":{"system":"sec-edgar","filing":"0001415889-25-018759","document":"form4-07012025_090735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588925018759/form4-07012025_090735.xml","form_type":"4"}},{"id":1098073,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-07-01T21:50:42.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":7541,"price":1.7,"value":12819.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":24050,"source":{"system":"sec-edgar","filing":"0001415889-25-018755","document":"form4-07012025_090738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588925018755/form4-07012025_090738.xml","form_type":"4"}},{"id":1097736,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":77854,"kind":"person","name":"Anderson Cynthia Lynn","position":1,"cik":"0001989905","reported_name":"Anderson Cynthia Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-07-01T21:49:44.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":6617,"price":1.7,"value":11248.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":12801,"source":{"system":"sec-edgar","filing":"0001415889-25-018751","document":"form4-07012025_090741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588925018751/form4-07012025_090741.xml","form_type":"4"}},{"id":1097739,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-01T21:48:28.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":7541,"price":1.7,"value":12819.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":18028,"source":{"system":"sec-edgar","filing":"0001415889-25-018748","document":"form4-07012025_090724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588925018748/form4-07012025_090724.xml","form_type":"4"}},{"id":1101868,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53119,"kind":"person","name":"Cote Elissa S.","position":1,"cik":"0002069951","reported_name":"Cote Elissa S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:16:37.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted in connection with the Reporting Person's appointment as Chief Corporate Development Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the stock options vest on June 23, 2026 (the \"Vesting Start Date\") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":1.96,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-25-018206","document":"form4-06252025_090633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2069951/000141588925018206/form4-06252025_090633.xml","form_type":"4"}},{"id":1101627,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":77854,"kind":"person","name":"Anderson Cynthia Lynn","position":1,"cik":"0001989905","reported_name":"Anderson Cynthia Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:15:12.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the \"Grant Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date."}],"balance_after":100000,"derivative":{"exercise_price":1.96,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-25-018203","document":"form4-06252025_050607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588925018203/form4-06252025_050607.xml","form_type":"4"}},{"id":1101626,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:15:09.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the \"Grant Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date."}],"balance_after":100000,"derivative":{"exercise_price":1.96,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-25-018202","document":"form4-06252025_050605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588925018202/form4-06252025_050605.xml","form_type":"4"}},{"id":1101799,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:15:07.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the \"Grant Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date."}],"balance_after":100000,"derivative":{"exercise_price":1.96,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-25-018201","document":"form4-06252025_050603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588925018201/form4-06252025_050603.xml","form_type":"4"}},{"id":1101628,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:15:06.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the \"Grant Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date."}],"balance_after":300000,"derivative":{"exercise_price":1.96,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001415889-25-018200","document":"form4-06252025_050601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588925018200/form4-06252025_050601.xml","form_type":"4"}},{"id":1304244,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-13T22:40:58.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":3310,"price":2.5075,"value":8299.825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019  Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":5981,"source":{"system":"sec-edgar","filing":"0001415889-25-001402","document":"form4-01132025_100154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588925001402/form4-01132025_100154.xml","form_type":"4"}},{"id":1304243,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":77854,"kind":"person","name":"Anderson Cynthia Lynn","position":1,"cik":"0001989905","reported_name":"Anderson Cynthia Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-13T22:39:30.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":2592,"price":2.5075,"value":6499.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019  Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":6184,"source":{"system":"sec-edgar","filing":"0001415889-25-001396","document":"form4-01132025_100126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588925001396/form4-01132025_100126.xml","form_type":"4"}},{"id":1410712,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75505,"kind":"person","name":"Curley Joanne","position":1,"cik":"0001857670","reported_name":"Curley Joanne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-10T21:00:12.000Z","date":"2024-09-06","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance (\"Grant Date\"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date."}],"balance_after":14100,"derivative":{"exercise_price":3.25,"expiration_date":"2034-09-06","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001415889-24-023147","document":"form4-09102024_050907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924023147/form4-09102024_050907.xml","form_type":"4"}},{"id":1410711,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":50893,"kind":"person","name":"Cunningham Ann Michelle","position":1,"cik":"0001764572","reported_name":"Cunningham Ann Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-10T21:00:10.000Z","date":"2024-09-06","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance (\"Grant Date\"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date."}],"balance_after":14100,"derivative":{"exercise_price":3.25,"expiration_date":"2034-09-06","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001415889-24-023146","document":"form4-09102024_050905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924023146/form4-09102024_050905.xml","form_type":"4"}},{"id":1410710,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-10T21:00:07.000Z","date":"2024-09-06","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance (\"Grant Date\"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date."}],"balance_after":14100,"derivative":{"exercise_price":3.25,"expiration_date":"2034-09-06","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001415889-24-023145","document":"form4-09102024_050903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924023145/form4-09102024_050903.xml","form_type":"4"}},{"id":1411422,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":87660,"kind":"person","name":"GIN JERRY B","position":1,"cik":"0000901014","reported_name":"GIN JERRY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-10T17:00:15.000Z","date":"2024-09-06","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance (\"Grant Date\"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date."}],"balance_after":14100,"derivative":{"exercise_price":3.25,"expiration_date":"2034-09-06","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001415889-24-023148","document":"form4-09102024_050909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/901014/000141588924023148/form4-09102024_050909.xml","form_type":"4"}},{"id":1411068,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75534,"kind":"person","name":"SAXE JON S","position":1,"cik":"0001114914","reported_name":"SAXE JON S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-10T17:00:15.000Z","date":"2024-09-06","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance (\"Grant Date\"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date."}],"balance_after":14100,"derivative":{"exercise_price":3.25,"expiration_date":"2034-09-06","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001415889-24-023149","document":"form4-09102024_050911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114914/000141588924023149/form4-09102024_050911.xml","form_type":"4"}},{"id":1411434,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75541,"kind":"person","name":"Rotunno Mary L.","position":1,"cik":"0001869200","reported_name":"Rotunno Mary L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-10T17:00:08.000Z","date":"2024-09-06","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance (\"Grant Date\"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date."}],"balance_after":14100,"derivative":{"exercise_price":3.25,"expiration_date":"2034-09-06","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001415889-24-023144","document":"form4-09102024_050901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869200/000141588924023144/form4-09102024_050901.xml","form_type":"4"}},{"id":1462617,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-07-02T22:10:04.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":2671,"price":2.958,"value":7900.818,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended."}],"balance_after":2671,"source":{"system":"sec-edgar","filing":"0001415889-24-019028","document":"form4-07022024_100701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924019028/form4-07022024_100701.xml","form_type":"4"}},{"id":1462615,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":77854,"kind":"person","name":"Anderson Cynthia Lynn","position":1,"cik":"0001989905","reported_name":"Anderson Cynthia Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-02T22:08:51.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":3592,"price":2.958,"value":10625.136,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended."}],"balance_after":3592,"source":{"system":"sec-edgar","filing":"0001415889-24-019024","document":"form4-07022024_100748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924019024/form4-07022024_100748.xml","form_type":"4"}},{"id":1463473,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHF CORP DEVEL OFF, GEN COUNS"}}],"security":"Common Stock","published_at":"2024-07-02T22:07:53.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":4854,"price":2.958,"value":14358.132,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended."}],"balance_after":16509,"source":{"system":"sec-edgar","filing":"0001415889-24-019022","document":"form4-07022024_100750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588924019022/form4-07022024_100750.xml","form_type":"4"}},{"id":1462619,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-07-02T22:06:41.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":4854,"price":2.958,"value":14358.132,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended."}],"balance_after":10487,"source":{"system":"sec-edgar","filing":"0001415889-24-019020","document":"form4-07022024_100738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588924019020/form4-07022024_100738.xml","form_type":"4"}},{"id":1468674,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T01:31:44.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the \"Vesting Start Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date."}],"balance_after":500000,"derivative":{"exercise_price":3.23,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001415889-24-018279","document":"form4-06272024_010639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588924018279/form4-06272024_010639.xml","form_type":"4"}},{"id":1468852,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHF CORP DEVEL OFF, GEN COUNS"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T01:30:57.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the \"Vesting Start Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date."}],"balance_after":170000,"derivative":{"exercise_price":3.23,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001415889-24-018278","document":"form4-06272024_010654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588924018278/form4-06272024_010654.xml","form_type":"4"}},{"id":1468673,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":77854,"kind":"person","name":"Anderson Cynthia Lynn","position":1,"cik":"0001989905","reported_name":"Anderson Cynthia Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T01:30:06.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the \"Vesting Start Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":3.23,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-24-018277","document":"form4-06272024_010602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924018277/form4-06272024_010602.xml","form_type":"4"}},{"id":1468672,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":53072,"kind":"person","name":"Prince Joshua S.","position":1,"cik":"0001998663","reported_name":"Prince Joshua S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T01:29:04.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (the \"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the \"Vesting Start Date\"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":3.23,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-24-018276","document":"form4-06272024_010600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924018276/form4-06272024_010600.xml","form_type":"4"}},{"id":1591378,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T23:00:20.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":12500,"derivative":{"exercise_price":4.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-007097","document":"form4-03062024_060311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924007097/form4-03062024_060311.xml","form_type":"4"}},{"id":1591376,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75505,"kind":"person","name":"Curley Joanne","position":1,"cik":"0001857670","reported_name":"Curley Joanne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T23:00:15.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":12500,"derivative":{"exercise_price":4.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-007096","document":"form4-03062024_060307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924007096/form4-03062024_060307.xml","form_type":"4"}},{"id":1591377,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":50893,"kind":"person","name":"Cunningham Ann Michelle","position":1,"cik":"0001764572","reported_name":"Cunningham Ann Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T23:00:10.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":12500,"derivative":{"exercise_price":4.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-007095","document":"form4-03062024_060304.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924007095/form4-03062024_060304.xml","form_type":"4"}},{"id":1592841,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75541,"kind":"person","name":"Rotunno Mary L.","position":1,"cik":"0001869200","reported_name":"Rotunno Mary L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T18:00:31.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":12500,"derivative":{"exercise_price":4.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-007099","document":"form4-03062024_060318.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869200/000141588924007099/form4-03062024_060318.xml","form_type":"4"}},{"id":1592777,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":87660,"kind":"person","name":"GIN JERRY B","position":1,"cik":"0000901014","reported_name":"GIN JERRY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T18:00:24.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":12500,"derivative":{"exercise_price":4.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-007098","document":"form4-03062024_060314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/901014/000141588924007098/form4-03062024_060314.xml","form_type":"4"}},{"id":1592318,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75534,"kind":"person","name":"SAXE JON S","position":1,"cik":"0001114914","reported_name":"SAXE JON S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T18:00:09.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":12500,"derivative":{"exercise_price":4.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-007094","document":"form4-03062024_060301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114914/000141588924007094/form4-03062024_060301.xml","form_type":"4"}},{"id":1693360,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHF CORP DEVEL OFF, GEN COUNS"}}],"security":"Common Stock","published_at":"2024-01-03T22:19:38.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":167,"price":1.717,"value":286.739,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased pursuant to the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan."}],"balance_after":11655,"source":{"system":"sec-edgar","filing":"0001415889-24-000350","document":"form4-01032024_100124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588924000350/form4-01032024_100124.xml","form_type":"4"}},{"id":1691730,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-03T22:17:08.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":167,"price":1.717,"value":286.739,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased pursuant to the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan."}],"balance_after":5633,"source":{"system":"sec-edgar","filing":"0001415889-24-000344","document":"form4-01032024_100142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588924000344/form4-01032024_100142.xml","form_type":"4"}},{"id":1763420,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche 2 Warrants (Right to Buy)","published_at":"2023-10-06T20:05:25.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":1690014,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2023, Vistagen Therapeutics, Inc. (the \"Issuer\") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share (\"Common Stock\") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the \"Tranche 1 Warrants\") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the \"Tranche 2 Warrants\"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the \"Pre-Funded Warrants\") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP (\"Commodore Capital\") is no longer a 10% beneficial owner of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Tranche 2 Warrants are exercisable from the date of issuance and expire on October 4, 2028. The Tranche 2 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 2 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 2 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1690014,"derivative":{"exercise_price":8.877,"exercise_date":"2023-10-04","expiration_date":"2028-10-04","underlying":"Common Stock","underlying_shares":1690014},"source":{"system":"sec-edgar","filing":"0001493152-23-036497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223036497/ownership.xml","form_type":"4"}},{"id":1763419,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche 1 Warrants (Right to Buy)","published_at":"2023-10-06T20:05:25.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":1394310,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2023, Vistagen Therapeutics, Inc. (the \"Issuer\") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share (\"Common Stock\") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the \"Tranche 1 Warrants\") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the \"Tranche 2 Warrants\"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the \"Pre-Funded Warrants\") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP (\"Commodore Capital\") is no longer a 10% beneficial owner of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Tranche 1 Warrants are exercisable from the date of issuance and expire 60 days after the later of (i) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-3 study and (ii) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-4 study. The Tranche 1 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 1 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 1 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1394310,"derivative":{"exercise_price":5.38,"exercise_date":"2023-10-04","underlying":"Common Stock","underlying_shares":1394310},"source":{"system":"sec-edgar","filing":"0001493152-23-036497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223036497/ownership.xml","form_type":"4"}},{"id":1763418,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2023-10-06T20:05:25.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":2788620,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2023, Vistagen Therapeutics, Inc. (the \"Issuer\") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share (\"Common Stock\") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the \"Tranche 1 Warrants\") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the \"Tranche 2 Warrants\"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the \"Pre-Funded Warrants\") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP (\"Commodore Capital\") is no longer a 10% beneficial owner of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable from the date of issuance until fully exercised. The Pre-funded Warrants contain an exercise limitation prohibiting Commodore Capital Master LP (\"Commodore Master\") from exercising the Pre-Funded Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Pre-funded Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2788620,"derivative":{"exercise_price":0.001,"exercise_date":"2023-10-04","underlying":"Common Stock","underlying_shares":2788620},"source":{"system":"sec-edgar","filing":"0001493152-23-036497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223036497/ownership.xml","form_type":"4"}},{"id":1798567,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":77854,"kind":"person","name":"Anderson Cynthia Lynn","position":1,"cik":"0001989905","reported_name":"Anderson Cynthia Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-23T17:09:47.000Z","date":"2023-08-21","kind":"grant","planned":false,"acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted in connection with the Reporting Person's appointment as Chief Financial Officer and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the stock options vest on August 21, 2024 (the \"Vesting Start Date\") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date."}],"balance_after":8333,"derivative":{"exercise_price":5.34,"expiration_date":"2033-08-21","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001415889-23-012532","document":"form4-08232023_050842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588923012532/form4-08232023_050842.xml","form_type":"4"}},{"id":1811892,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-09T20:10:18.000Z","date":"2023-08-07","kind":"purchase","planned":false,"acquired":true,"shares":775756,"price":23.153,"value":17961078.668,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.00 to $25.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1575000,"source":{"system":"sec-edgar","filing":"0001493152-23-027352","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223027352/ownership.xml","form_type":"4"}},{"id":1835752,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-07-05T20:05:17.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":167,"price":1.5895,"value":265.4465,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan (\"ESPP\")."}],"balance_after":5466,"source":{"system":"sec-edgar","filing":"0001415889-23-010721","document":"form4-07052023_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588923010721/form4-07052023_040705.xml","form_type":"4"}},{"id":1836880,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2023-07-05T20:05:12.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":167,"price":1.5895,"value":265.4465,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan (\"ESPP\")."}],"balance_after":11488,"source":{"system":"sec-edgar","filing":"0001415889-23-010720","document":"form4-07052023_040703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588923010720/form4-07052023_040703.xml","form_type":"4"}},{"id":1835750,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO"}}],"security":"Common Stock","published_at":"2023-07-05T20:05:07.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":167,"price":1.5895,"value":265.4465,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan (\"ESPP\")."}],"balance_after":3671,"source":{"system":"sec-edgar","filing":"0001415889-23-010719","document":"form4-07052023_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588923010719/form4-07052023_040701.xml","form_type":"4"}},{"id":2072467,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2023-01-03T21:11:11.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":5000,"price":0.0876,"value":438.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan (\"ESPP\")."}],"balance_after":105111,"source":{"system":"sec-edgar","filing":"0001415889-23-000043","document":"form4-01032023_090100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588923000043/form4-01032023_090100.xml","form_type":"4"}},{"id":2072474,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-01-03T21:10:52.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":5000,"price":0.0876,"value":438.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan (\"ESPP\")."}],"balance_after":158998,"source":{"system":"sec-edgar","filing":"0001415889-23-000041","document":"form4-01032023_090116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588923000041/form4-01032023_090116.xml","form_type":"4"}},{"id":2177357,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":87660,"kind":"person","name":"GIN JERRY B","position":1,"cik":"0000901014","reported_name":"GIN JERRY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-22T17:12:50.000Z","date":"2022-08-18","kind":"purchase","acquired":true,"shares":100000,"price":0.1787,"value":17870.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1772 to $0.1805, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001415889-22-008937","document":"form4-08222022_020840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/901014/000141588922008937/form4-08222022_020840.xml","form_type":"4"}},{"id":2177356,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":87660,"kind":"person","name":"GIN JERRY B","position":1,"cik":"0000901014","reported_name":"GIN JERRY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-22T17:12:50.000Z","date":"2022-08-18","kind":"purchase","acquired":true,"shares":100000,"price":0.1787,"value":17870.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1772 to $0.1805, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001415889-22-008937","document":"form4-08222022_020840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/901014/000141588922008937/form4-08222022_020840.xml","form_type":"4"}},{"id":2178495,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2022-08-19T19:45:10.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":300000,"price":0.1697,"value":50910.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1689 to $0.1701, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":334629,"source":{"system":"sec-edgar","filing":"0001415889-22-008894","document":"form4-08192022_030801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588922008894/form4-08192022_030801.xml","form_type":"4"}},{"id":2179434,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-08-18T19:56:47.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":600000,"price":0.172,"value":103200.0,"ownership":{"direct":false,"nature":"By The 1997 Singh Family Trust U/R/D 05/29/97"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1600 to $0.1975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":626234,"source":{"system":"sec-edgar","filing":"0001415889-22-008814","document":"form4-08182022_120836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588922008814/form4-08182022_120836.xml","form_type":"4"}},{"id":2206875,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2022-07-15T20:30:54.000Z","date":"2022-07-30","kind":"grant","acquired":true,"shares":5000,"price":0.748,"value":3740.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan (\"ESPP\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes shares held by the Reporting Person as of the date of this Form 4, but inadvertently excluded from previously filed reports."}],"balance_after":100111,"source":{"system":"sec-edgar","filing":"0001415889-22-007686","document":"form4-07152022_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922007686/form4-07152022_040701.xml","form_type":"4"}},{"id":2206880,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-07-15T20:30:29.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":5000,"price":0.748,"value":3740.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)"}],"balance_after":153998,"source":{"system":"sec-edgar","filing":"0001415889-22-007688","document":"form4-07152022_040717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588922007688/form4-07152022_040717.xml","form_type":"4"}},{"id":2206873,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":125352,"kind":"person","name":"Smith Mark Alan","position":1,"cik":"0001677452","reported_name":"Smith Mark Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2022-07-15T20:30:27.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":5000,"price":0.748,"value":3740.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)"}],"balance_after":19915,"source":{"system":"sec-edgar","filing":"0001415889-22-007687","document":"form4-07152022_040709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922007687/form4-07152022_040709.xml","form_type":"4"}},{"id":2207747,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":122870,"kind":"organization","name":"Venrock Healthcare Capital Partners II, L.P.","position":1,"cik":"0001602264","reported_name":"Venrock Healthcare Capital Partners II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122871,"kind":"organization","name":"VHCP Co-Investment Holdings II, LLC","position":2,"cik":"0001615983","reported_name":"VHCP Co-Investment Holdings II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106510,"kind":"organization","name":"VHCP Management II, LLC","position":3,"cik":"0001602263","reported_name":"VHCP Management II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":55705,"kind":"organization","name":"Venrock Healthcare Capital Partners III, L.P.","position":4,"cik":"0001738048","reported_name":"Venrock Healthcare Capital Partners III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":55706,"kind":"organization","name":"VHCP Co-Investment Holdings III, LLC","position":5,"cik":"0001750761","reported_name":"VHCP Co-Investment Holdings III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":55709,"kind":"organization","name":"VHCP Management III, LLC","position":6,"cik":"0001738053","reported_name":"VHCP Management III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":55708,"kind":"organization","name":"Venrock Healthcare Capital Partners EG, L.P.","position":7,"cik":"0001808512","reported_name":"Venrock Healthcare Capital Partners EG, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":55707,"kind":"organization","name":"VHCP Management EG, LLC","position":8,"cik":"0001808518","reported_name":"VHCP Management EG, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":55710,"kind":"person","name":"Koh Bong Y","position":9,"cik":"0001615979","reported_name":"Koh Bong Y","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1948,"kind":"person","name":"Shah Nimish P","position":10,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-14T17:33:58.000Z","date":"2022-07-12","kind":"sale","acquired":false,"shares":60000,"price":0.89,"value":53400.0,"ownership":{"direct":false,"nature":"By Funds"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of 14,348 shares sold by Venrock Healthcare Capital Partners II, L.P. (\"VHCP II\"), 5,814 shares sold by VHCP Co-Investment Holdings II, LLC (\"VHCP II Co\"), 4,688 shares sold by Venrock Healthcare Capital Partners III, L.P. (\"VHCP III\"), 469 shares sold by VHCP Co-Investment Holdings III, LLC (\"VHCP III Co\") and 34,681 shares sold by Venrock Healthcare Capital Partners EG, L.P. (\"VHCP EG\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consists of 4,935,020 shares held by VHCP II, 1,999,971 shares held by VHCP II Co, 1,612,582 shares held by VHCP III, 161,351 shares held by VHCP III Co and 11,928,362 shares held by VHCP EG."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"VHCP Management II, LLC (\"VHCPM II\") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC (\"VHCPM III\") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC (\"VHCPM EG\") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II, VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM II, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III, VHCP III Co and VHCP EG, except to the extent of their respective indirect pecuniary interests therein."}],"balance_after":20637286,"source":{"system":"sec-edgar","filing":"0001209191-22-042152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808518/000120919122042152/doc4.xml","form_type":"4"}},{"id":2270176,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-16T17:39:31.000Z","date":"2022-05-12","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock option vested 25% on the grant date of September 5, 2019, with the remainder vesting monthly over the 36 months thereafter."}],"balance_after":70000,"derivative":{"exercise_price":1,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-004988","document":"form4-05162022_100519.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588922004988/form4-05162022_100519.xml","form_type":"4"}},{"id":2270175,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-16T17:39:31.000Z","date":"2022-05-12","kind":"exercise","acquired":true,"shares":100000,"price":1,"value":100000.0,"ownership":{"direct":true},"balance_after":148998,"source":{"system":"sec-edgar","filing":"0001415889-22-004988","document":"form4-05162022_100519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588922004988/form4-05162022_100519.xml","form_type":"4"}},{"id":2284656,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32993,"kind":"person","name":"Adler Reid G.","position":1,"cik":"0001924908","reported_name":"Adler Reid G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Options (right to buy)","published_at":"2022-05-03T21:10:46.000Z","date":"2022-05-02","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the stock options vest on May 2, 2023 (the \"Vesting Start Date\") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date."}],"balance_after":200000,"derivative":{"exercise_price":1.28,"expiration_date":"2032-05-02","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-22-004542","document":"form4-05032022_020513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924908/000141588922004542/form4-05032022_020513.xml","form_type":"4"}},{"id":2353757,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:17:16.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan.  Twenty-five percent (25%) of the total number of shares vest immediately on March 1, 2022 (the \"Vesting Start Date\") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-22-002300","document":"form4-03032022_010304.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922002300/form4-03032022_010304.xml","form_type":"4"}},{"id":2353756,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":125352,"kind":"person","name":"Smith Mark Alan","position":1,"cik":"0001677452","reported_name":"Smith Mark Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:16:28.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan.  Twenty-five percent (25%) of the total number of shares vest immediately on March 1, 2022 (the \"Vesting Start Date\") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-22-002297","document":"form4-03032022_010306.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922002297/form4-03032022_010306.xml","form_type":"4"}},{"id":2353755,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":50893,"kind":"person","name":"Cunningham Ann Michelle","position":1,"cik":"0001764572","reported_name":"Cunningham Ann Michelle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:15:33.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan.  Twenty-five percent (25%) of the total number of shares vest immediately on March 1, 2022 (the \"Vesting Start Date\") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date."}],"balance_after":150000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-22-002296","document":"form4-03032022_010313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922002296/form4-03032022_010313.xml","form_type":"4"}},{"id":2353768,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:14:29.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan.  Twenty-five percent (25%) of the total number of shares vest immediately on March 1, 2022 (the \"Vesting Start Date\") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date."}],"balance_after":300000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001415889-22-002294","document":"form4-03032022_010311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588922002294/form4-03032022_010311.xml","form_type":"4"}},{"id":2353754,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:13:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":100000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-002291","document":"form4-03032022_010341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922002291/form4-03032022_010341.xml","form_type":"4"}},{"id":2353753,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75505,"kind":"person","name":"Curley Joanne","position":1,"cik":"0001857670","reported_name":"Curley Joanne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:10:24.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":100000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-002287","document":"form4-03032022_010302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922002287/form4-03032022_010302.xml","form_type":"4"}},{"id":2356976,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":87660,"kind":"person","name":"GIN JERRY B","position":1,"cik":"0000901014","reported_name":"GIN JERRY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T16:13:45.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":100000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-002292","document":"form4-03032022_010333.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/901014/000141588922002292/form4-03032022_010333.xml","form_type":"4"}},{"id":2355847,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75534,"kind":"person","name":"SAXE JON S","position":1,"cik":"0001114914","reported_name":"SAXE JON S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T16:12:01.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":100000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-002290","document":"form4-03032022_010344.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114914/000141588922002290/form4-03032022_010344.xml","form_type":"4"}},{"id":2357247,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75541,"kind":"person","name":"Rotunno Mary L.","position":1,"cik":"0001869200","reported_name":"Rotunno Mary L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T16:11:08.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":100000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-002289","document":"form4-03032022_010355.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869200/000141588922002289/form4-03032022_010355.xml","form_type":"4"}},{"id":2436709,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-12T22:21:47.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this stock option vested May 23, 2019, with the the remaining shares vesting in 1/36th installments on each monthly anniversary thereafter."}],"balance_after":15625,"derivative":{"exercise_price":1,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":34375},"source":{"system":"sec-edgar","filing":"0001415889-22-000507","document":"form4-01122022_020137.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922000507/form4-01122022_020137.xml","form_type":"4"}},{"id":2436708,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2022-01-12T22:21:47.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":18750,"price":1,"value":18750.0,"ownership":{"direct":true},"balance_after":94571,"source":{"system":"sec-edgar","filing":"0001415889-22-000507","document":"form4-01122022_020137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922000507/form4-01122022_020137.xml","form_type":"4"}},{"id":2454097,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":125352,"kind":"person","name":"Smith Mark Alan","position":1,"cik":"0001677452","reported_name":"Smith Mark Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2022-01-03T21:25:20.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":2655,"price":1.6575,"value":4400.6625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)"}],"balance_after":14915,"source":{"system":"sec-edgar","filing":"0001415889-22-000046","document":"form4-01032022_010104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922000046/form4-01032022_010104.xml","form_type":"4"}},{"id":2454096,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2022-01-03T21:20:34.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":3575,"price":1.6575,"value":5925.5625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)"}],"balance_after":75821,"source":{"system":"sec-edgar","filing":"0001415889-22-000041","document":"form4-01032022_010120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922000041/form4-01032022_010120.xml","form_type":"4"}},{"id":2454104,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":32789,"kind":"person","name":"Singh Shawn","position":1,"cik":"0001412071","reported_name":"Singh Shawn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-01-03T21:17:51.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":3623,"price":1.6575,"value":6005.1225,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)"}],"balance_after":48998,"source":{"system":"sec-edgar","filing":"0001415889-22-000034","document":"form4-01032022_010137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412071/000141588922000034/form4-01032022_010137.xml","form_type":"4"}},{"id":2454110,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":131828,"kind":"person","name":"SNODGRASS H. RALPH","position":1,"cik":"0001415876","reported_name":"SNODGRASS H. RALPH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES./CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2022-01-03T16:19:23.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":3623,"price":1.6575,"value":6005.1225,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)"}],"balance_after":64958,"source":{"system":"sec-edgar","filing":"0001415889-22-000038","document":"form4-01032022_010112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415876/000141588922000038/form4-01032022_010112.xml","form_type":"4"}},{"id":2575823,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2021-09-08T22:58:15.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":30000,"price":3.125,"value":93750.0,"ownership":{"direct":true},"balance_after":72786,"source":{"system":"sec-edgar","filing":"0001415889-21-004287","document":"form4-09082021_030907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588921004287/form4-09082021_030907.xml","form_type":"4"}},{"id":2579012,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":131828,"kind":"person","name":"SNODGRASS H. RALPH","position":1,"cik":"0001415876","reported_name":"SNODGRASS H. RALPH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES./CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2021-09-03T16:19:03.000Z","date":"2021-09-02","kind":"gift","acquired":true,"shares":1111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person received the shares reported herein in connection with the distribution of securities from a family trust, of which the Reporting Person is a beneficiary."}],"balance_after":61335,"source":{"system":"sec-edgar","filing":"0001415889-21-004226","document":"form4-09032021_010953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415876/000141588921004226/form4-09032021_010953.xml","form_type":"4"}},{"id":2579011,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":131828,"kind":"person","name":"SNODGRASS H. RALPH","position":1,"cik":"0001415876","reported_name":"SNODGRASS H. RALPH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES./CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2021-09-03T16:19:03.000Z","date":"2021-08-23","kind":"gift","acquired":false,"shares":740,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By H. Ralph Snodgrass Living Trust, dated 10/2/2008"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of securities from the Reporting Person to certain family members who do not share the Reporting Person's household."}],"balance_after":33901,"source":{"system":"sec-edgar","filing":"0001415889-21-004226","document":"form4-09032021_010953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415876/000141588921004226/form4-09032021_010953.xml","form_type":"4"}},{"id":2597656,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":131828,"kind":"person","name":"SNODGRASS H. RALPH","position":1,"cik":"0001415876","reported_name":"SNODGRASS H. RALPH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES./CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2021-08-18T18:20:36.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":3750,"price":2.73,"value":10237.5,"ownership":{"direct":false,"nature":"By H. Ralph Snodgrass Living Trust, dated 10/2/2008"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes shares previously held by the Reporting Person directly, but subsequently transferred to the H. Ralph Snodgrass Living Trust, dated 10/2/2008."}],"balance_after":34641,"source":{"system":"sec-edgar","filing":"0001415889-21-004002","document":"form4-08182021_030825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415876/000141588921004002/form4-08182021_030825.xml","form_type":"4"}},{"id":2627079,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-22T20:11:26.000Z","date":"2021-07-21","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in twelve equal monthly installments, beginning on the date of the grant. The stock options were granted in connection with the Reporting Person's appointment to the Issuer's Board of Directors and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan."}],"balance_after":75000,"derivative":{"exercise_price":2.93,"expiration_date":"2031-07-21","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-21-003674","document":"form4-07222021_010706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588921003674/form4-07222021_010706.xml","form_type":"4"}},{"id":2640120,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":75541,"kind":"person","name":"Rotunno Mary L.","position":1,"cik":"0001869200","reported_name":"Rotunno Mary L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-07T16:49:02.000Z","date":"2021-07-06","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in twelve equal monthly installments, beginning on the date of the grant. The stock options were granted in connection with the Reporting Person's appointment to the Issuer's Board of Directors and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan."}],"balance_after":75000,"derivative":{"exercise_price":3.33,"expiration_date":"2031-07-06","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-21-003544","document":"form4-07072021_010752.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869200/000141588921003544/form4-07072021_010752.xml","form_type":"4"}},{"id":2644256,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":125352,"kind":"person","name":"Smith Mark Alan","position":1,"cik":"0001677452","reported_name":"Smith Mark Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2021-07-02T20:11:08.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":2260,"price":1.9465,"value":4399.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2021 in a transaction exempt under Rule 16b-3(c)."}],"balance_after":12260,"source":{"system":"sec-edgar","filing":"0001415889-21-003388","document":"form4-07022021_040710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588921003388/form4-07022021_040710.xml","form_type":"4"}},{"id":2644255,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:10:59.000Z","date":"2021-06-30","kind":"exercise","acquired":false,"shares":9824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the total number of shares began vesting  immediately on April 23, 2020, with the remaining shares vesting in 1/24th monthly installments thereafter."}],"balance_after":140176,"derivative":{"exercise_price":0.398,"expiration_date":"2030-04-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-21-003391","document":"form4-07022021_040729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588921003391/form4-07022021_040729.xml","form_type":"4"}},{"id":2644254,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:10:59.000Z","date":"2021-06-30","kind":"exercise","acquired":false,"shares":78918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this stock option vested May 23, 2019, with the  the remaining shares vesting in 1/36th installments on each monthly anniversary thereafter."}],"balance_after":34375,"derivative":{"exercise_price":1,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":113293},"source":{"system":"sec-edgar","filing":"0001415889-21-003391","document":"form4-07022021_040729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588921003391/form4-07022021_040729.xml","form_type":"4"}},{"id":2644253,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":111610,"kind":"person","name":"DOTSON JERROLD DUANE","position":1,"cik":"0001388853","reported_name":"DOTSON JERROLD DUANE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO AND SECRETARY"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:10:59.000Z","date":"2021-06-30","kind":"disposition_to_issuer","acquired":false,"shares":36707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents stock options that were cancelled and returned to the Issuer in order to pay the exercise price associated with the exercise reported herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this stock option vested May 23, 2019, with the  the remaining shares vesting in 1/36th installments on each monthly anniversary thereafter."}],"balance_after":113293,"derivative":{"exercise_price":1,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-21-003391","document":"form4-07022021_040729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588921003391/form4-07022021_040729.xml","form_type":"4"}}],"next_cursor":"2021-07-02T20:10:59.000000Z,2644253"}